Back to News
Market Impact: 0.3

Should You Retain Henry Schein Stock in Your Portfolio Right Now?

HSICALGNABTCOR
Company FundamentalsCorporate EarningsM&A & RestructuringTechnology & InnovationArtificial IntelligenceCybersecurity & Data PrivacyEconomic DataHealthcare & Biotech
Should You Retain Henry Schein Stock in Your Portfolio Right Now?

Henry Schein, Inc. (HSIC) is exhibiting growth, primarily driven by its Henry Schein One dental software joint venture, which is expanding with AI and cybersecurity solutions and showing strong customer adoption, alongside strategic acquisitions like Acentus. While HSIC has outperformed its industry and the S&P 500 over the past year and consistently beaten earnings, it faces significant operational pressures from macroeconomic headwinds—including inflation and exchange rate fluctuations that are impacting margins—and intense competition across its healthcare distribution and animal health markets.

Analysis

Henry Schein (HSIC) presents a mixed operational profile, characterized by strategic growth drivers offset by significant macroeconomic and competitive headwinds. On the positive side, the company's stock has outperformed its industry and the S&P 500 over the past year with a 15.3% gain, supported by four consecutive quarters of earnings beats. Growth is primarily fueled by the Henry Schein One joint venture, which is successfully expanding its dental software offerings in AI, revenue cycle management, and cybersecurity, evidenced by a nearly 20% year-over-year increase in subscribers for its key platforms. Furthermore, HSIC's inorganic growth strategy remains intact through niche acquisitions like Acentus and R. Weinstein, which expand its product lines and geographic reach. However, these tailwinds are counterbalanced by tangible financial pressures. Macroeconomic challenges contributed to a 0.4% increase in the cost of sales and a 1.2% decline in gross profit during the first quarter, resulting in a 34-basis-point contraction in gross margin. The outlook remains tempered, with the 2025 consensus EPS estimate of $4.87 unchanged and revenue projected to grow a modest 2.3%, reflecting the persistent margin pressure and intense competition in its markets.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo